How to collect data for FDA and CMS in the same study

Gregory De Lissovoy

Research output: Contribution to journalArticle

Abstract

The FDA and CMS perspectives on evidence from clinical trials and suggestions for planning studies that will address the information needs of both agencies are discussed. Planning a trial that can satisfy both FDA and CMS is challenging because the agencies have fundamentally different missions. CMS can grant provisional Medicare coverage for a new procedure contingent on the development and capture of additional patient data to supplement standard claims data. FDA is a regulatory agency with the power to control the marketing of medical products. CMS must examine many other sources of data when formulating the National Coverage Determination (NCD). Careful attention to the design of these reports can facilitate resource coding. Trial designers should address whether including CMS concerns in an FDA submission could muddle the data FDA uses to make the basic regulatory approval. Planning for coverage approval should include supporting studies based on literature synthesis, patient survey research, or economic modeling.

Original languageEnglish (US)
JournalMedical Device and Diagnostic Industry
Volume29
Issue number4
StatePublished - 2007
Externally publishedYes

Fingerprint

Planning
Information Storage and Retrieval
Medicare
Marketing
Economics
Clinical Trials
Research
Surveys and Questionnaires

ASJC Scopus subject areas

  • Medicine(all)
  • Mechanical Engineering
  • Materials Science(all)

Cite this

How to collect data for FDA and CMS in the same study. / De Lissovoy, Gregory.

In: Medical Device and Diagnostic Industry, Vol. 29, No. 4, 2007.

Research output: Contribution to journalArticle

@article{52e7a15be7bb4041b93104b121ca0593,
title = "How to collect data for FDA and CMS in the same study",
abstract = "The FDA and CMS perspectives on evidence from clinical trials and suggestions for planning studies that will address the information needs of both agencies are discussed. Planning a trial that can satisfy both FDA and CMS is challenging because the agencies have fundamentally different missions. CMS can grant provisional Medicare coverage for a new procedure contingent on the development and capture of additional patient data to supplement standard claims data. FDA is a regulatory agency with the power to control the marketing of medical products. CMS must examine many other sources of data when formulating the National Coverage Determination (NCD). Careful attention to the design of these reports can facilitate resource coding. Trial designers should address whether including CMS concerns in an FDA submission could muddle the data FDA uses to make the basic regulatory approval. Planning for coverage approval should include supporting studies based on literature synthesis, patient survey research, or economic modeling.",
author = "{De Lissovoy}, Gregory",
year = "2007",
language = "English (US)",
volume = "29",
journal = "Medical Device and Diagnostic Industry",
issn = "0194-844X",
publisher = "Canon Communications LLC",
number = "4",

}

TY - JOUR

T1 - How to collect data for FDA and CMS in the same study

AU - De Lissovoy, Gregory

PY - 2007

Y1 - 2007

N2 - The FDA and CMS perspectives on evidence from clinical trials and suggestions for planning studies that will address the information needs of both agencies are discussed. Planning a trial that can satisfy both FDA and CMS is challenging because the agencies have fundamentally different missions. CMS can grant provisional Medicare coverage for a new procedure contingent on the development and capture of additional patient data to supplement standard claims data. FDA is a regulatory agency with the power to control the marketing of medical products. CMS must examine many other sources of data when formulating the National Coverage Determination (NCD). Careful attention to the design of these reports can facilitate resource coding. Trial designers should address whether including CMS concerns in an FDA submission could muddle the data FDA uses to make the basic regulatory approval. Planning for coverage approval should include supporting studies based on literature synthesis, patient survey research, or economic modeling.

AB - The FDA and CMS perspectives on evidence from clinical trials and suggestions for planning studies that will address the information needs of both agencies are discussed. Planning a trial that can satisfy both FDA and CMS is challenging because the agencies have fundamentally different missions. CMS can grant provisional Medicare coverage for a new procedure contingent on the development and capture of additional patient data to supplement standard claims data. FDA is a regulatory agency with the power to control the marketing of medical products. CMS must examine many other sources of data when formulating the National Coverage Determination (NCD). Careful attention to the design of these reports can facilitate resource coding. Trial designers should address whether including CMS concerns in an FDA submission could muddle the data FDA uses to make the basic regulatory approval. Planning for coverage approval should include supporting studies based on literature synthesis, patient survey research, or economic modeling.

UR - http://www.scopus.com/inward/record.url?scp=70350389005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350389005&partnerID=8YFLogxK

M3 - Article

VL - 29

JO - Medical Device and Diagnostic Industry

JF - Medical Device and Diagnostic Industry

SN - 0194-844X

IS - 4

ER -